Sign In
Buy SRPT
$16.24
-0.0100 (-0.0615%)
At Close: Jun 03, 2026
Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript)
06:48pm, Thursday, 10'th Jun 2021
Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript)
Sarepta Therapeutics to Present at Upcoming Investor Conferences
04:30pm, Thursday, 03'rd Jun 2021
CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will pa
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:55pm, Friday, 28'th May 2021
CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 28, 2021 that were
3 Popular Stocks Money Managers Couldn't Stop Selling in Q1
06:06am, Friday, 28'th May 2021
Institutional investors and hedge funds wanted nothing to do with these widely owned stocks in the first quarter.
Sarepta (SRPT) Rises on Robust DMD Gene Therapy Study Data
09:46am, Wednesday, 19'th May 2021
Sarepta's (SRPT) lead gene therapy candidate, SRP-9001, demonstrates robust improvement in expression of micro-dystrophin protein in DMD patients after 12 weeks of treatment.
Sarepta Therapeutics (SRPT) Moves 8.4% Higher: Will This Strength Last?
09:01am, Wednesday, 19'th May 2021
Sarepta Therapeutics (SRPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price i
Why Sarepta Therapeutics (SRPT) Stock Soared on Tuesday
10:32pm, Tuesday, 18'th May 2021
Shares of Sarepta Therapeutics (SRPT) closed higher after announcing positive data for its Duchenne Muscular Dystrophy (DMD) drug.
Sarepta Therapeutics, Inc. (SRPT) Presents at RBC Capital Markets Global Healthcare Broker Conference Call - (Transcript)
05:09pm, Tuesday, 18'th May 2021
Sarepta Therapeutics, Inc. (SRPT) Presents at RBC Capital Markets Global Healthcare Broker Conference Call - (Transcript)
Sarepta's stock is up 11% on positive data from clinical trial for Duchenne treatment
12:53pm, Tuesday, 18'th May 2021
Shares of Sarepta Therapeutics Inc. gained 11.3% in trading on Tuesday after the company shared positive data from a mid-stage, open-label clinical trial for its experimental Duchenne muscular dystrop
CAMBRIDGE, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced positive 12-week expression and
CAMBRIDGE, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Tuesday, May 18, 2021 a
5 Growth Stocks Down 50% (or More) With Upside of 62% to 133%, According to Wall Street
05:51am, Tuesday, 11'th May 2021
Analysts believe these fast-growing, innovative businesses are excellent bounce-back candidates over the next 12 months.
Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates
12:01pm, Thursday, 06'th May 2021
Sarepta (SRPT) Q1 revenues increase year over year. The company is progressing well with its pipeline.
Why Sarepta's Q1 Results Won't Spark a Rebound for the Beaten-Down Biotech
06:10am, Thursday, 06'th May 2021
The company's revenue soared in Q1, but its bottom line still looked ugly.
Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q1 2021 Results - Earnings Call Transcript
12:00am, Thursday, 06'th May 2021
Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q1 2021 Results - Earnings Call Transcript
